These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38604387)

  • 1. B-cell characteristics define HCV reinfection outcome.
    Underwood AP; Gupta M; Wu BR; Eltahla AA; Boo I; Wang JJ; Agapiou D; Abayasingam A; Reynaldi A; Keoshkerian E; Zhao Y; Brasher N; Walker MR; Bukh J; Maher L; Gordon T; Davenport MP; Luciani F; Drummer HE; Lloyd AR; Bull RA
    J Hepatol; 2024 Sep; 81(3):415-428. PubMed ID: 38604387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell immunodominance in primary hepatitis C virus infection.
    Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA
    J Hepatol; 2020 Apr; 72(4):670-679. PubMed ID: 31785346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinated expansion of memory T follicular helper and B cells mediates spontaneous clearance of HCV reinfection.
    Eisa M; Gomez-Escobar E; Bédard N; Abdeltawab NF; Flores N; Mazouz S; Fieffé-Bédard A; Sakayan P; Gridley J; Abdel-Hakeem MS; Bruneau J; Grakoui A; Shoukry NH
    Front Immunol; 2024; 15():1403769. PubMed ID: 38947319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.
    Osburn WO; Fisher BE; Dowd KA; Urban G; Liu L; Ray SC; Thomas DL; Cox AL
    Gastroenterology; 2010 Jan; 138(1):315-24. PubMed ID: 19782080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    Merat SJ; Bru C; van de Berg D; Molenkamp R; Tarr AW; Koekkoek S; Kootstra NA; Prins M; Ball JK; Bakker AQ; de Jong MD; Spits H; Beaumont T; Schinkel J
    J Hepatol; 2019 Jul; 71(1):14-24. PubMed ID: 30797052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection.
    Walker MR; Eltahla AA; Mina MM; Li H; Lloyd AR; Bull RA
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31936235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C cross-genotype immunity and implications for vaccine development.
    Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Wong J; Tyndall MW; Janjua NZ;
    Sci Rep; 2017 Sep; 7(1):12326. PubMed ID: 28951612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signatures of protective memory immune responses during hepatitis C virus reinfection.
    Abdel-Hakeem MS; Bédard N; Murphy D; Bruneau J; Shoukry NH
    Gastroenterology; 2014 Oct; 147(4):870-881.e8. PubMed ID: 25038432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Bankwitz D; Bahai A; Labuhn M; Doepke M; Ginkel C; Khera T; Todt D; Ströh LJ; Dold L; Klein F; Klawonn F; Krey T; Behrendt P; Cornberg M; McHardy AC; Pietschmann T
    Gut; 2021 Sep; 70(9):1734-1745. PubMed ID: 33323394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential immune transcriptomic profiles between vaccinated and resolved HCV reinfected subjects.
    Mazouz S; Salinas E; Bédard N; Filali A; Khedr O; Swadling L; Abdel-Hakeem MS; Siddique A; Barnes E; Bruneau J; Grakoui A; Shoukry NH
    PLoS Pathog; 2022 Nov; 18(11):e1010968. PubMed ID: 36378682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
    Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH
    PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies.
    Walker MR; Leung P; Eltahla AA; Underwood A; Abayasingam A; Brasher NA; Li H; Wu BR; Maher L; Luciani F; Lloyd AR; Bull RA
    Sci Rep; 2019 Sep; 9(1):13300. PubMed ID: 31527718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.
    Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M
    Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.
    Osburn WO; Snider AE; Wells BL; Latanich R; Bailey JR; Thomas DL; Cox AL; Ray SC
    Hepatology; 2014 Jun; 59(6):2140-51. PubMed ID: 24425349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated LAG-3 on CD4
    Zhang J; Liu W; Xie T; Huang L; Hu Y; Wen B; Tang P; Guo F; Jin K; Zhang P; Niu L; Liu Z; Qu X
    Immunol Lett; 2019 Aug; 212():46-52. PubMed ID: 31216427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of neutralizing antibodies in hepatitis C virus infection.
    Edwards VC; Tarr AW; Urbanowicz RA; Ball JK
    J Gen Virol; 2012 Jan; 93(Pt 1):1-19. PubMed ID: 22049091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.